AKAP9 Antibody

Immunocytochemistry/Immunofluorescence: AKAP9 Antibody [NB100-1517] - analysis of paraformaldehyde fixed A431 cells, permeabilized with 0.15% Triton. Primary incubation 1hr (10ug/ml) followed by Alexa Fluor 488 secondary antibody (4ug/ml), showing cytoplasmic and Golgi apparatus staining. The nuclear stain is DAPI (blue). Negative control: Unimmunized goat IgG (10ug/ml) followed by Alexa Fluor 488 secondary antibody (4ug/ml).

Immunocytochemistry/Immunofluorescence: AKAP9 Antibody [NB100-1517] - analysis of paraformaldehyde fixed U2OS cells, permeabilized with 0.15% Triton. Primary incubation 1hr (10ug/ml) followed by Alexa Fluor 488 secondary antibody (4ug/ml), showing cytoplasmic staining. The nuclear stain is DAPI (b

• Reactivity: Hu, Rt
• Applications: WB, ELISA, ICC/IF
• Clonality: Polyclonal
• Host: Goat
• Conjugate: Unconjugated
• Concentration: 0.5 mg/ml

AKAP9 Antibody Summary

• Immunogen: Peptide with sequence C-SGSTTQFHAGMR corresponding to C-Terminus according to NP_005742.4, NP_671714.1.
• Specificity: This antibody is expected to recognise isoforms 2 and 3 (NP_005742.4; NP_671714.1 respectively). The isoforms Yotiao, AKAP350B and AKAP350C are not recognized.
• Isotype: IgG
• Clonality: Polyclonal
• Host: Goat
• Gene: AKAP9
• Purity: Immunogen affinity purified

Applications/Dilutions

• Dilutions:
  • Immunocytochemistry/ Immunofluorescence 10ug/ml
  • Peptide ELISA 1:32000
  • Western Blot 1-3 ug/ml
• Application Notes: Western blot: This product has been successfully used by a customer, showing a band at approx 450kDa in lysates of cell line HepG2 (calculated MW of 453kDa according to NP_005742.4).
  Immunofluorescence: Strong expression of the protein seen in the cytoplasm of A431 and U2OS cells.
• Theoretical MW: 450 kDa.
  Disclaimer note: The observed molecular weight of the protein may vary from the listed predicted molecular weight due to post translational modifications, post translation cleavages, relative charges, and other experimental factors.

Reactivity Notes

Rat reactivity reported in scientific literature. (PMID: 21177871). Expected from sequence similarity: Mouse

Packaging, Storage & Formulations

• Storage: Store at -20C. Avoid freeze-thaw cycles.
• Buffer: Tris saline (20 mM Tris pH 7.3, 150 mM NaCl), 0.5% BSA
• Preservative: 0.02% Sodium Azide
• Concentration: 0.5 mg/ml
• Purity: Immunogen affinity purified

Alternate Names for AKAP9 Antibody

• A kinase (PRKA) anchor protein (yotiao) 9
• AKAP 350
• AKAP 450
• AKAP350A-kinase anchor protein 450 kDa
• AKAP450A-kinase anchor protein 350 kDa
• AKAP-9
• Centrosome- and Golgi-localized PKN-associated protein
• CG-NAPAKAP 120-like protein
• hgAKAP 350
• HYPERION
• KIAA0803A-kinase anchor protein 9
• MU-RMS-40.16A
• PRKA9AKAP9-BRAF fusion protein
• Protein hyperion
• protein kinase A anchoring protein 9
• Protein kinase A-anchoring protein 9
• Protein yotiao
• YOTIAOkinase N-associated protein

Background

The A-kinase anchor proteins (AKAPs) are a group of structurally diverse proteins which have the common function of binding to the regulatory subunit of protein kinase A (PKA) and confining the holoenzyme to discrete locations within the cell. This gene encodes a member of the AKAP family. Alternate splicing of this gene results in many isoforms that localize to the centrosome and the Golgi apparatus, and interact with numerous signaling proteins from multiple signal transduction pathways. These signaling proteins include type II protein kinase A, serine/threonine kinase protein kinase N, protein phosphatase 1, protein phosphatase 2a, protein kinase C-epsilon and phosphodiesterase 4D3.

Limitations

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.

Publications for AKAP9 Antibody (NB100-1517)(2)

Publications using NB100-1517

• Christian F, Szaszak M, Friedl S et al. Small molecule AKAP/PKA interaction disruptors that activate PKA interfere with compartmentalized cAMP signaling in cardiac myocytes. J Biol Chem. 2011-01-01 [PMID: 21177871]
• Ciampi R, Knauf JA, Kerler R et al. Oncogenic AKAP9-BRAF fusion is a novel mechanism of MAPK pathway activation in thyroid cancer. J Clin Invest 2005-01-01 [PMID: 15630448]

Review for AKAP9 Antibody (NB100-1517) (1)

Average Rating: 4

(Based on 1 review)

We have 1 review tested in 1 species: Rat.

reviewed by: Marta Szaszak WB Rat 10/04/2011

Summary

• Application: Western Blot
• Sample Tested: neonatal cardiac myocytes
• Species: Rat

Bioinformatics

• Gene Symbol: AKAP9
• Entrez:
  • 10142(Human)
• Uniprot:
  • Q99996(Human)